Test Price
2,800 AED✅ Home Collection Available
FBLN5 Gene Cutis Laxa Type 2, Autosomal Dominant Genetic Test in UAE
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 accredited NGS processing.
Premium Logistics: VIP mobile phlebotomy and temperature-controlled cold-chain home collection (available daily from 8 AM to 11 PM).
Clinical Guidance: Post‑test telephonic result interpretation with a genetic expert.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The FBLN5 gene NGS test detects pathogenic variants causing autosomal dominant Cutis Laxa Type 2, a connective tissue disorder characterized by loose, sagging skin and potential vascular complications. This single‑gene analysis is recommended for individuals with clinical skin laxity or a positive family history, enabling precise molecular diagnosis and informed genetic counselling.
| Feature | Our Test (NGS Full‑Gene Sequencing) | Closest Alternative (Single‑variant PCR) |
|---|---|---|
| Methodology | Next‑Generation Sequencing (NGS) – covers entire FBLN5 coding region | Targeted PCR for known familial mutation |
| Diagnostic Yield | >99.9% sensitivity for point mutations, small indels | Limited to one specific variant; misses novel mutations |
| Turnaround Time | 3–4 weeks | 6–8 weeks |
| Sample Type | Whole blood, extracted DNA, or one drop blood on FTA card | Blood only |
| Clinical Utility | Definitive diagnosis, family screening, prenatal options | Carrier screening for known familial mutation |
Physician Insight & Safety Protocols
"As a Consultant Medical Genetics, I emphasize that the results of this genetic test must always be interpreted within the full clinical picture. A positive FBLN5 variant confirms the diagnosis but does not necessarily predict severity; a negative result does not exclude the condition if clinical signs are strong. Regular follow‑up with your dermatologist and a medical geneticist is essential."
— Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
⚠️ Medication Advisory & Exclusion Criteria
Medication Warning: Do not discontinue any prescribed medication without consulting your treating physician. Blood pressure or vascular medications should never be stopped abruptly because of a genetic test result.
- Exclusion criteria: Known severe coagulopathy, inability to tolerate venipuncture, or lack of signed informed consent. For FTA card sampling, ensure the card is not contaminated.
- ER red flags after blood draw: Excessive bleeding, large hematoma, fainting, or signs of infection (redness, warmth, fever) — seek immediate medical attention.
- Minors: In compliance with UAE Federal Decree-Law No. 4 of 2016 on Medical Liability, all genetic tests on individuals under 18 require legal guardian consent and a post‑test genetic counselling session.
Patient FAQ & Clinical Guidance
1. What is the FBLN5 gene test and why is it ordered?
This NGS‑based test examines the entire FBLN5 gene to identify mutations responsible for autosomal dominant Cutis Laxa Type 2, a disorder that causes progressive skin laxity and may affect blood vessels. It is ordered by a dermatologist, clinical geneticist, or sports medicine specialist when a patient presents with unexplained sagging skin, vascular fragility, or a family history of the condition.
2. How is the test performed and which samples are accepted?
A certified phlebotomist collects a small blood sample via standard venipuncture; alternatively, a single drop of blood dried on an FTA card or previously extracted DNA can be used. The entire process follows UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 concerning health data. Your sample is transported in an ISO‑certified cold‑chain to our genomics laboratory.
3. What do my results mean if they are positive or negative for an FBLN5 mutation?
A positive result confirms a pathogenic variant associated with Cutis Laxa Type 2, guiding your clinical team in surveillance for vascular complications and informing family screening. A negative result does not completely rule out the condition because non‑coding or deep intronic mutations may not be detected; ongoing clinical evaluation remains crucial.
UAE Regulatory & Data Privacy Adherence
Data Privacy Compliance: All patient data is handled in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Genetic information is encrypted and access is restricted to authorized clinical personnel only.
Medical Liability: Patient safety and consent protocols strictly follow Federal Decree-Law No. 4 of 2016 on Medical Liability. Your rights as a patient, including informed consent and the right to withdraw, are fully protected.
Clinical & Logistical Metadata
| Test Name | FBLN5 Gene Cutis Laxa Type 2, Autosomal Dominant Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 14–21 business days |
| Sample Type / Matrix | Whole blood, FTA card (dried blood spot), or extracted DNA. VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available. |
| Methodology Used | Next-Generation Sequencing (NGS) – full gene sequencing covering all coding exons and intron-exon boundaries |
| ICD-10-CM Code | Q82.8 (Other specified congenital malformations of skin) |
| LOINC Code | 81304-2 (FBLN5 gene sequencing) |
| DHA Facility License & Address | DHA Facility License Number: 1143 Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE Corporate Lab Branding: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians